🏛️ Verified NIH Record • Updated 2026-08-07
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies (NCT06584955)
🔵 Active, Not Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: M.D. Anderson Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical research study is to learn about the effects of weighted blankets on sleep quality in patients with blood cancers. Weighted blankets are heavier blankets that contain inner weight beads. The deep pressure stimulation induced by these blankets can have a calming effect.
Who can join: Review the eligibility criteria below.
Location: The University of Texas MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
- Weighted Blanket (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The University of Texas MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematological Malignancies
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
- Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma — Duarte, California
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies — Houston, Texas
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Hematological Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.